View source for Certolizumab pegol

{{Short description|Pharmaceutical drug}}
{{Use mdy dates|date=August 2023}}
{{cs1 config |name-list-style=vanc |display-authors=6}}
{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = 460025906
| type = mab
| image = CertolizumaB 5WUV.png 
| image_class = bg-transparent
| alt = 
| image2 = Syringe with Certolizumab pegol-1800.jpg
| alt2 = 
| caption = Syringe with 200mg Certolizumab pegol

<!-- Monoclonal antibody data -->
| mab_type = Fab'
| source = zu/o
| target = [[TNF alpha]]

<!-- Clinical data -->
| tradename = Cimzia
| Drugs.com = {{drugs.com|monograph|certolizumab-pegol}}
| MedlinePlus = a608041
| DailyMedID = Certolizumab pegol
| pregnancy_AU = C
| pregnancy_category = 
| routes_of_administration = [[Subcutaneous administration|Subcutaneous]]
| ATC_prefix = L04
| ATC_suffix = AB05

| legal_AU = S4
| legal_CA = 
| legal_UK = 
| legal_US = Rx-only
| legal_US_comment = <ref name="Cimzia FDA label" />
| legal_EU = Rx-only
| legal_EU_comment = <ref name="Cimzia EPAR" />
| legal_status = 

<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = about 11 days
| excretion = [[Kidney]] ([[Macrogol|PEG]] only)

<!-- Identifiers -->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 428863-50-7
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB08904
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
| UNII_Ref = {{fdacite|changed|FDA}}
| UNII = UMD07X179E
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D03441
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1201831
| synonyms = CDP870

<!-- Chemical data -->
| C=2115 | H=3252 | N=556 | O=673 | S=16
}}

'''Certolizumab pegol''', sold under the brand name '''Cimzia''', is a [[biopharmaceutical]] medication for the treatment of [[Crohn's disease]],<ref name="pmid17634458">{{cite journal | vauthors = Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, Mason D, Bloomfield R, Schreiber S | display-authors = 6 | title = Certolizumab pegol for the treatment of Crohn's disease | journal = The New England Journal of Medicine | volume = 357 | issue = 3 | pages = 228–238 | date = July 2007 | pmid = 17634458 | doi = 10.1056/NEJMoa067594 | doi-access = free }}</ref><ref>{{cite journal | vauthors = Goel N, Stephens S | title = Certolizumab pegol | journal = mAbs | volume = 2 | issue = 2 | pages = 137–147 | year = 2010 | pmid = 20190560 | pmc = 2840232 | doi = 10.4161/mabs.2.2.11271 }}</ref> [[rheumatoid arthritis]], [[psoriatic arthritis]] and [[ankylosing spondylitis]]. It is a fragment of a [[monoclonal antibody]] specific to [[tumor necrosis factor alpha]] (TNF-α) and is manufactured by [[UCB (company)|UCB]].<ref name="pmid15934837">{{cite journal | vauthors = Kaushik VV, Moots RJ | title = CDP-870 (certolizumab) in rheumatoid arthritis | journal = Expert Opinion on Biological Therapy | volume = 5 | issue = 4 | pages = 601–606 | date = April 2005 | pmid = 15934837 | doi = 10.1517/14712598.5.4.601 | s2cid = 21974683 }}</ref><ref name="Cimzia Label and Approval History">{{cite web | title=Drug Approval Package: Cimzia (Certolizumab Pegol) NDA #125160 | website=U.S. [[Food and Drug Administration]] (FDA) | date=December 24, 1999 | url=https://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | archive-url=https://web.archive.org/web/20150215072924/http://www.accessdata.fda.gov/drugsatfda_docs/nda/2008/125160s000TOC2.cfm | url-status=dead | archive-date=February 15, 2015 | access-date=July 18, 2020}}</ref><ref name="Cimzia FDA label">{{cite web | title=Cimzia- certolizumab pegol kit Cimzia- certolizumab pegol injection, solution | website=DailyMed | date=April 24, 2020 | url=https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b4c2c9dc-a0bb-4d64-a667-a67ebe88392d | access-date=July 18, 2020}}</ref>

It is on the [[WHO Model List of Essential Medicines|World Health Organization's List of Essential Medicines]].<ref name="WHO23rd">{{cite book | vauthors = ((World Health Organization)) | title = The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023) | year = 2023 | hdl = 10665/371090 | author-link = World Health Organization | publisher = World Health Organization | location = Geneva | id = WHO/MHP/HPS/EML/2023.02 | hdl-access=free }}</ref>

==Medical uses==

;Crohn's Disease: On April 22, 2008, the U.S. [[Food and Drug Administration]] (FDA) approved Cimzia for the treatment of Crohn's disease in people who did not respond sufficiently or adequately to standard therapy.<ref name="Cimzia Label and Approval History"/><ref>{{cite web | url = http://www.ucb.com/media-room/newsdetail/?det=1314787 | work = UCB press release | title = Cimzia Approved in the US for the Treatment of Moderate to Severe Crohn's Disease | archive-url = https://web.archive.org/web/20120218234442/http://www.ucb.com/media-room/newsdetail/?det=1314787 | archive-date = February 18, 2012 | access-date = April 22, 2008 }}</ref><ref>{{cite web | url = http://www.medscape.com/viewarticle/573833 | title = FDA Approvals: Patanase, Actonel, Cimzia | vauthors = Waknine Y | date = May 1, 2008 | publisher = [[Medscape]] | access-date = May 1, 2008}}</ref>

;Rheumatoid arthritis: On June 26, 2009, the [[Committee for Medicinal Products for Human Use]] (CHMP) of the [[European Medicines Agency]] (EMA) issued a positive opinion recommending that the European Commission grant a marketing authorisation for Cimzia for the treatment of rheumatoid arthritis only - the CHMP refused approval for the treatment of Crohn's disease. The marketing authorisation was granted to UCB Pharma SA in October 2009.<ref name="Cimzia EPAR">{{cite web | url=https://www.ema.europa.eu/en/medicines/human/EPAR/cimzia-0 | title=Cimzia EPAR | date=October 22, 2009 | publisher=[[European Medicines Agency]] | access-date=November 15, 2009 | archive-url=https://web.archive.org/web/20091109064625/http://www.emea.europa.eu/humandocs/Humans/EPAR/cimzia/cimzia.htm | archive-date=November 9, 2009 | url-status=live }}</ref>

;Psoriatic arthritis: On September 27, 2013, the [[Food and Drug Administration (United States)|U.S. FDA]] approved Cimzia for the treatment of adult patients with active [[psoriatic arthritis]].<ref>{{cite web | url=http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx | title=Cimzia (certolizumab pegol) approved by the U.S. FDA for treatment of adult patients with active psoriatic arthritis | access-date=October 1, 2013 | url-status=dead | archive-url=https://archive.today/20131001130038/http://www.ucb.presscentre.com/News/Cimzia-certolizumab-pegol-approved-by-the-U-S-FDA-for-treatment-of-adult-patients-with-active-ps-45c.aspx | archive-date=October 1, 2013 }}</ref>

== Method of action ==
[[File:Certolizumab binding TNF-alpha homotrimer 5WUX.png|left|thumb|Three certolizumab molecules (blue) binding a [[homotrimer]] of TNF-alpha (tan). Certolizumab can block TNF in both its soluble form (freely circulating in the bloodstream) and its [[transmembrane]] form (bound to the membrane of a cell). From {{PDB|5WUX}}.<ref>{{cite journal | vauthors = Lee JU, Shin W, Son JY, Yoo KY, Heo YS | title = Molecular Basis for the Neutralization of Tumor Necrosis Factor α by Certolizumab Pegol in the Treatment of Inflammatory Autoimmune Diseases | journal = International Journal of Molecular Sciences | volume = 18 | issue = 1 | page = 228 | date = January 2017 | pmid = 28124979 | pmc = 5297857 | doi = 10.3390/ijms18010228 | doi-access = free }}</ref>]]
Certolizumab pegol is a monoclonal antibody directed against [[tumor necrosis factor alpha]]. More precisely, it is a [[PEGylated]] [[Fragment antigen-binding|Fab']] fragment of a humanized [[TNF inhibitor]] monoclonal antibody.<ref name="Schreiber" />

==Clinical trials==

;Crohn's disease: Positive results have been demonstrated in two phase III trials (PRECiSE 1 and 2) of certolizumab pegol versus [[placebo]] in moderate to severe active Crohn's disease.<ref name="pmid17634458" /><ref name="Schreiber">{{cite journal | vauthors = Schreiber S, Khaliq-Kareemi M, Lawrance I, Hanauer S, McColm J, Bloomfield R, Sandborn W | title = Certolizumab pegol, a humanised anti-TNF pegylated FAb' fragment, is safe and effective in the maintenance of response and remission following induction in active Crohn's disease: a phase 3 study (precise) | journal = Gut | date = 2005 | volume = 54 | issue = suppl 7 | page = A82 }}</ref><ref>{{cite journal | vauthors = Sandborn WJ, Feagan BG, Stoinov S, Honiball PJ, Rutgeerts P, McColm JA, Innes A, Schreiber S | title = Certolizumab pegol administered subcutaneously is effective and well tolerated in patients with active Crohn's disease: results from a 26-week, placebo-controlled Phase 3 study (PRECiSE 1) | journal = Gastroenterology | date = 2006 | volume = 130 | issue = 4 | page = A107 }}</ref><ref>{{cite press release| url = http://ir.ucb-group.com/phoenix.zhtml?c=137495&p=irol-newsArticle&ID=919693| title = New Analysis Shows Cimzia (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease| date = October 23, 2006| publisher = UCB| access-date = November 15, 2009| archive-date = March 29, 2020| archive-url = https://web.archive.org/web/20200329052421/http://ir.ucb-group.com/phoenix.zhtml?c=137495&p=irol-newsArticle&ID=919693| url-status = dead}}</ref>

;Axial spondyloarthritis: In 2013, a phase 3 double blind randomized placebo-controlled study found significantly positive results in patient self-reported questionnaires, with rapid improvement of function and pain reduction, in patients with [[axial spondyloarthritis]].<ref>{{cite journal|vauthors=Sieper J, Tubergen A, Coteur G, Woltering F, Landewe R | title=PMS50 – Rapid Improvements In Patient-Reported Outcomes With Certolizumab Pegol In Patients With Axial Spondyloarthritis, Including Ankylosing Spondylitis And Non-Radiographic Axial Spondyloarthritis: 24-Week Results Of A Phase 3 Double Blind Randomized Placebo-Controlled Study| date = May 2013| journal = Value in Health| volume = 16| issue = 3| pages = A227| doi = 10.1016/j.jval.2013.03.1150| doi-access = free}}</ref>

;Rheumatoid arthritis: Certolizumab appears beneficial in those with [[rheumatoid arthritis]].<ref name=Cochrane2017>{{cite journal | vauthors = Ruiz Garcia V, Burls A, Cabello JB, Vela Casasempere P, Bort-Marti S, Bernal JA | title = Certolizumab pegol (CDP870) for rheumatoid arthritis in adults | journal = The Cochrane Database of Systematic Reviews | volume = 2017 | issue = 9 | pages = CD007649 | date = September 2017 | pmid = 28884785 | pmc = 6483724 | doi = 10.1002/14651858.CD007649.pub4 }}</ref>
{{clear left}}
== References ==
{{reflist}}

== External links ==
* {{MeshName|certolizumab+pegol}}

{{Immunosuppressants}}
{{Monoclonals for immune system}}
{{Portal bar | Medicine}}
{{Authority control}}

[[Category:Biotechnology]]
[[Category:TNF inhibitors]]
[[Category:Immunosuppressants]]
[[Category:Belgian inventions]]
[[Category:World Health Organization essential medicines]]
[[Category:Monoclonal antibodies]]
[[Category:Disease-modifying antirheumatic drugs]]